{'fraction_non_alphanumeric': 0.024518388791593695, 'fraction_numerical': 0.0, 'mean_word_length': 4.896907216494846, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Treatment Issues in Patients With HIV/HCV Co-Infection.

DD The basic decision making is essentially the same, with the exception that HCV infection progresses more rapidly in HIV-positive patients than it does in those who are HIV-negative, in terms of the development of liver fibrosis and cirrhosis, warranting an earlier and more aggressive schedule of treatment. In addition, HIV medications can cause liver toxicity, which is heightened by HCV co-infection. It is therefore important to have the HCV enzymes under control to improve tolerance of HIV drug therapies.